重新将钠碘同向转运体引入未分化甲状腺癌
本研究采用基于线性聚乙烯亚胺(LPEI)、经聚乙二醇(PEG)屏蔽并偶联GE11肽的纳米颗粒载体,将钠碘同向转运体(NIS)基因靶向递送至表皮生长因子受体(EGFR)过表达的人甲状腺癌细胞。在未分化甲状腺癌(ATC)异种移植小鼠模型中,全身给药后123I显像显示肿瘤特异性放射性碘聚集,131I治疗使SW1736移植瘤生长显著减小并延长生存。数据为非病毒 reintroduction NIS 基因后ATC的核素显像与治疗提供了新思路。
要点
- LPEI-PEG-GE11/NIS在SW1736和Hth74 ATC细胞中显示高转染效率及EGFR特异性。
- 全身注射后123I显像显示SW1736和Hth74移植瘤特异性放射性碘聚集,SW1736更高。
- 131I治疗使LPEI-PEG-GE11/NIS处理的SW1736移植瘤小鼠肿瘤生长显著减小、生存延长。
核心结论
- 数据为ATC经非病毒方式重新引入NIS基因后实现NIS介导的核素显像与治疗开辟了前景。
- 全身应用后的高肿瘤特异性使该策略成为治疗高度转移性ATC的有吸引力的替代方案。
研究设计与样本
- 研究采用基于线性聚乙烯亚胺(LPEI)、经聚乙二醇(PEG)屏蔽并偶联合成肽GE11(EGFR特异性配体)的纳米颗粒载体(polyplexes),将NIS表达质粒(LPEI-PEG-GE11/NIS)靶向递送至EGFR过表达的人甲状腺癌细胞系。
- 使用ATC异种移植小鼠模型评估123I闪烁显像的转染效率及全身polyplex应用后系统性放射性碘治疗的潜力。
主要发现
- 在SW1736和Hth74 ATC细胞以及作为对照的更多分化的滤泡状(FTC-133)和乳头状(BCPAP)甲状腺癌细胞中,体外碘摄取研究显示LPEI-PEG-GE11/NIS的高转染效率和EGFR特异性,且与EGFR表达水平良好相关。
- 全身polyplex注射后,体内123I伽马相机显像显示SW1736和Hth74异种移植小鼠模型中肿瘤特异性放射性碘积聚。
- SW1736肿瘤中放射性碘积聚更高,与体外结果、EGFR表达水平及离体NIS染色分析结果一致。
- 在LPEI-PEG-GE11/NIS处理的SW1736异种移植小鼠中给予131I,与对照动物相比肿瘤生长显著减小并伴有生存延长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anaplastic thyroid carcinoma (ATC), the most aggressive form of thyroid cancer, is unresponsive to radioiodine therapy. The current study aimed to extend the diagnostic and therapeutic application of radioiodine beyond the treatment of differentiated thyroid cancer by targeting the functional sodium-iodide symporter (NIS) to ATC. METHODS: The study employed nanoparticle vectors (polyplexes) based on linear polyethylenimine (LPEI), shielded by polyethylene glycol (PEG) and coupled to the synthetic peptide GE11 as an epidermal growth factor receptor (EGFR)-specific ligand in order to target a NIS-expressing plasmid (LPEI-PEG-GE11/NIS) to EGFR overexpressing human thyroid carcinoma cell lines. Using ATC xenograft mouse models, transfection efficiency by 123I scintigraphy and potential for systemic radioiodine therapy after systemic polyplex application were evaluated. RESULTS: In vitro iodide uptake studies in SW1736 and Hth74 ATC cells, and, for comparison, in more differentiated follicular (FTC-133) and papillary (BCPAP) thyroid carcinoma cells demonstrated high transfection efficiency and EGFR-specificity of LPEI-PEG-GE11/NIS that correlated well with EGFR expression levels. After systemic polyplex injection, in vivo 123I gamma camera imaging revealed significant tumor-specific accumulation of radioiodine in an SW1736 and an Hth74 xenograft mouse model. Radioiodine accumulation was found to be higher in SW1736 tumors, reflecting in vitro results, EGFR expression levels, and results from ex vivo analysis of NIS staining. Administration of 131I in LPEI-PEG-GE11/NIS-treated SW1736 xenograft mice resulted in significantly reduced tumor growth associated with prolonged survival compared to control animals. CONCLUSIONS: The data open the exciting prospect of NIS-mediated radionuclide imaging and therapy of ATC after non-viral reintroduction of the NIS gene. The high tumor specificity after systemic application makes the strategy an attractive alternative for the treatment of highly metastatic ATC.
引用
- Schmohl KA, Dolp P, Schug C, et al. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma. Thyroid. 2017. PMID: 29032724. doi:10.1089/thy.2017.0290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。